Author : Naina mohamed pakkir maideen
Keyword : Drug interactions; sitagliptin; saxagliptin; linagliptin; gemigliptin;teneligliptin; vildagliptin; anagliptin; cyp3a4; p-gp efflux pump
Subject : Diabetes
Article Type : Review article
DOI : 10.13105/wjma.v7.i4.156
Article QR Code
Article File : Full Text PDF
Abstract : Dipeptidyl peptidase 4 (DPP4) inhibitors are oral antidiabetic drugs approved to manage type 2 diabetes mellitus. Saxagliptin is a substrate of CYP3A4/5 enzymes while other DPP4 inhibitors such as sitagliptin, linagliptin, gemigliptin and teneligliptin are weak substrates of CYP3A4. DPP4 inhibitors have also been identified as substrates of P-gp. Hence, the drugs inhibiting or inducing CYP3A4/5 enzymes and/or P-gp can alter the pharmacokinetics of DPP4 inhibitors. This review is aimed to identify the drugs interacting with DPP4 inhibitors. The plasma concentrations of saxagliptin have been reported to be increased significantly by the concomitant administration of ketoconazole or diltiazem while no significant interactions between various DPP4 inhibitors and drugs like warfarin, digoxin or cyclosporine have been identified.
Article by : Naina Mohamed Pakkir Maideen
Article add date : 2021-12-21
How to cite : Naina mohamed pakkir maideen. (2021-December-21). Drug interactions of dipeptidyl peptidase 4 inhibitors involving cyp enzymes and p-gp efflux pump. retrieved from https://www.openacessjournal.com/abstract/942